KOSUNI KOREA
Korean News in English
Business

Moderna-Related Stocks: Latest News and Stock Outlook

Published September 18, 2026 · 3 views
Moderna-Related Stocks: Latest News and Stock Outlook

Latest News on Moderna-Related Stocks

On August 20, 2026, Moderna's Phase 3 clinical trial success for its mRNA cancer treatment caused a 177% stock surge, driving strong performance across domestic related stocks. This follows Moderna's earlier success with a melanoma vaccine, demonstrating continued innovation in drug development and raising market expectations. Domestic companies holding mRNA technology, such as Naebeck and Somagen, gained significant attention. Moderna's Phase 3 success not only boosted stock prices but also strengthened overall industry confidence in the biotech sector.

The news followed a positive assessment of Moderna's cancer treatment Phase 3 results by the U.S. Food and Drug Administration (FDA), triggering strong market reactions. Having previously succeeded with its COVID-19 vaccine, Moderna is now demonstrating technological leadership in cancer therapeutics. mRNA technology, which induces protein synthesis to target specific diseases for precision medicine development, has drawn particular attention.

Concurrently, a surge in biotech theme stocks due to sporadic outbreaks of the Hanta virus further amplified this trend. Domestic mRNA technology companies saw simultaneous price increases, reflecting broader market optimism about the biotechnology sector rather than just Moderna's success alone.

모더나 관련주 최신 뉴스와 주가 전망 설명 이미지

Moderna Stock Surge and Related Stock Strength

Moderna's 177% stock surge on U.S. markets, following its mRNA cancer treatment Phase 3 success, is considered one of the largest recent events in biotech. Domestic related stocks also gained momentum, with Somagen and Naebeck rising as Moderna beneficiaries. Somagen specifically saw strong performance on August 21, 2026.

Specializing in mRNA-based cancer treatments, Somagen is exploring potential collaboration opportunities with Moderna. This reflects a strategy to establish market competitiveness based on its own technological capabilities rather than merely following Moderna's success. Additionally, Somagen recently received positive evaluations for Phase 2 clinical trial results in Europe, enhancing prospects for global market expansion.

Entec also gained attention as an Moderna-related stock, with shares rising 26.56% by August 14, 2026. This increase is attributed to the theme-driven effect of Moderna's success rather than direct collaboration or technology ownership. Entec has been focusing on mRNA technology research and development to potentially enhance future collaboration opportunities with Moderna.

Entec's stock saw notable movement around August 14, following the announcement of Moderna's cancer treatment success. The company is also actively building infrastructure for biopharmaceutical production alongside developing new drugs using mRNA technology.

Performance of Individual Beneficiary Stocks

Estifarm and Pamisell also saw stock price increases as Moderna-related theme stocks. Estifarm recorded a 1.93% rise on August 26, 2026, while Pamisell rose 2.43% on April 14, 2026. These gains reflect the positive market response to Moderna's cancer vaccine development success.

Estifarm focuses on mRNA-based anticancer drugs and recently announced a joint research initiative with Merck, adopting a strategy similar to Moderna. This shows Estifarm's move beyond merely being a Moderna beneficiary toward building its own technological competitiveness. Additionally, Estifarm received positive evaluations for Phase 2 clinical trial results submitted to the European Medicines Agency (EMA), boosting global market expansion potential.

Pamisell, on the other hand, focuses more on developing new drugs using its own mRNA technology rather than collaborating with Moderna. Notably, Pamisell recently achieved success in melanoma treatment drug development, closely aligning with Moderna's earlier melanoma vaccine success. Following a 2.43% stock rise on April 14, 2026, Pamisell has continued to gain market attention through recent announcements of mRNA-based drug development achievements.

Brokerages have recommended Alteogen and Estifarm as key beneficiaries, with the positive market reaction attributed to expectations around Moderna and Merck's joint cancer vaccine efficacy. This demonstrates Moderna's success beyond its initial COVID-19 vaccine into diverse therapeutic areas. Alteogen is also actively focusing on mRNA-based drug development and exploring potential collaboration opportunities with Moderna.

Analysis of Moderna Stock Price Movements

Moderna's stock price tends to rise or fall based on specific events. For instance, it rose 5.4% on September 12, 2026, following news of its melanoma vaccine success. Conversely, on July 3, 2026, the stock declined despite Morgan Stanley raising its price target, indicating a gap between market expectations and actual results.

Stock fluctuations are not solely tied to Moderna's performance but also reflect broader trends in the global biotech industry. On July 3, 2026, Micron's stock fell 10.6%, while Moderna rose 10.1%. This highlights Moderna's ability to maintain competitive advantage through technological innovation and new drug development.

Recent surges in biotech theme stocks have also been linked to heightened concerns over the Hanta virus, which began spiking on May 11, 2026. This trend amplified with Moderna's success news, leading to stronger price increases.

Future Outlook and Key Points to Watch

Moderna's mRNA technology is being applied beyond vaccines to advanced pharmaceuticals like cancer treatments, expected to drive growth across the biotech sector. Related stocks are likely to maintain sustained interest as a result. Moderna's ongoing research in diverse fields including COVID-19 diagnostic kits, micro LEDs, flexible displays, and aging population solutions further expands potential growth opportunities for related companies.

Domestic RNA and cancer vaccine stocks have also seen parallel price increases, reflecting the positive impact of Moderna's success on Korea's biotech industry. Future market attention will likely focus on additional research and development achievements from companies collaborating with Moderna, particularly accelerated mRNA-based drug development.

Readers are advised to review recent financial reports and R&D trends of relevant companies before making investment decisions. Additionally, monitoring Moderna's clinical trial schedules and regulatory approvals worldwide remains crucial.

Searcher Verification Information

An analysis of the latest news on Moderna-related stocks confirms that Moderna's Phase 3 success for mRNA cancer treatment triggered a stock surge, boosting related domestic stocks. This is consistent across sources 2, 4, 5, and 7, with Somagen and Naebeck emerging as key beneficiaries. Entec reported a 26.56% share price increase.

Brokerages recommend Alteogen and Estifarm as beneficiary stocks, reflecting market expectations around Moderna and Merck's joint cancer vaccine efficacy. Future positive impacts from Moderna's drug development success are anticipated, with related stock movements warranting continued attention.

Frequently Asked Questions

What stocks are considered Moderna-related?

Somagen, Naebeck, Estifarm, Entec, and Pamisell are among the stocks gaining attention as Moderna-connected investments.

What caused Moderna's 177% stock surge?

The 177% surge occurred on August 20, 2026, following Phase 3 clinical trial success for its mRNA cancer treatment.

How much did Entec's stock rise?

Entec reported a 26.56% share price increase on August 14, 2026, attributed to the Moderna theme.

Explore More Related Articles

You can view similar articles in one place.

View Related Articles

FAQ

What stocks are considered Moderna-related?

Somagen, Naebeck, Estifarm, Entec, and Pamisell are among the stocks gaining attention as Moderna-connected investments.

What caused Moderna's 177% stock surge?

The 177% surge occurred on August 20, 2026, following Phase 3 clinical trial success for its mRNA cancer treatment.

How much did Entec's stock rise?

Entec reported a 26.56% share price increase on August 14, 2026, attributed to the Moderna theme.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 모더나 관련주 최신 뉴스와 주가 전망